hepcure
hepcure
HepCure Webinars
220 posts
HepCure tele-education is a weekly forum for interprofessional learning on Hepatitis C that brings together the key stakeholders (medical providers, patients, behavioral health care providers, pharmacists, care coordinators, patient navigators, public health experts, policy makers, and activists)  to discuss issues related to Hepatitis C treatment and cure and learn from each other
Don't wanna be here? Send us removal request.
hepcure · 7 years ago
Text
We are moving to the HepCure.org Site
All archived webinars and upcoming webinars can now be found on our new HepCure.org website!
On our new site, you can find:
Information for patients about our patient app and HCV resources
Information for providers about our provider dashboard
Announcements for upcoming webinars
All of our archived webinars
Our new Beginner Modules for providers interested in becoming HCV-experienced providers (10 CEs available for the 10 module set)
And more!
If you have any questions, email us at [email protected]
7 notes · View notes
hepcure · 7 years ago
Text
Join our LIVE Webinar on Tuesday, September 19 on "Overcoming barriers to hepatitis C elimination: Our Baltimore experience"
Please join us on Tuesday, September 12th at 4:30 PM EST for a presentation by Dr. Seun Falade-Nwulia of Johns Hopkins Medical Center. Dr. Falade-Nwulia will present: "Overcoming barriers to hepatitis C elimination: Our Baltimore experience" Presenter Bio: Currently an assistant professor at the Johns Hopkins University School of Medicine, Dr. Seun Falade-Nwulia's clinical pursuits are focused on care of HIV and HCV infected patients and educating clinicians and public health practitioners about STDs, HIV, and hepatitis. She served as Medical Director of the Baltimore City Health Department Sexually Transmitted Diseases Clinic based HIV care programs until 2015 and also developed and implemented the Baltimore City Health Department HCV testing, linkage to care and treatment programs, establishing the Baltimore City Health Department as a national leader in health department population HCV control programs. Her research has focused on understanding the distribution and impact of highly active antiretroviral therapy on hepatitis B and C outcomes, and on improving HIV and HCV testing and access to care in medically underserved communities. A particular focus of her research is understanding the transmission of and care uptake for HCV using social network and molecular (such as phylogenic) tools; as a bridge to development of sustainable interventions to increase HCV cure rates, prevent HCV transmission and reinfection and thus control HCV at the population level.
Click here to join!
2 notes · View notes
hepcure · 7 years ago
Text
Join our LIVE Webinar on Tuesday, September 12 on “INHSU 2017 Conference Update”
Please join us on Tuesday, September 12th at 4:30 PM EST for a presentation by Dr. Alain Litwin of Montefiore Medical Center. Dr. Litwin will present: "INHSU 2017 Conference Update" Presenter Bio: With funding from NIH, CDC, AHRQ, the Robert Wood Johnson Foundation, New York State Department of Health, New York City Department of Health, and industry, Dr. Alain Litwin’s research is focused on developing and studying models of hepatitis C virus (HCV) care for drug users, and on advocating for increasing access to effective care for HCV-infected patients. Dr. Litwin has worked with government and community organizations on efforts to expand access to HCV treatment and has collaborated on policy statements, clinical guidelines, task forces, strategic plans, and educational curricula with the New York City Department of Health and Mental Hygiene, New York State Department of Health, Substance Abuse and Mental Health Service Administration, Center for Substance Abuse Treatment, Centers for Disease Control and Prevention, and the American Society of Addiction Medicine. Dr. Litwin is board certified in internal medicine and addiction medicine, and has been providing medical care to drug users with complex social, psychiatric and medical needs within an integrated primary care and methadone maintenance treatment program for thirteen years. After joining Einstein’s Division of Substance Abuse (DoSA), he helped develop a comprehensive on-site HCV treatment program, including HCV support groups and a peer educator program, to improve medical care of HCV-infected drug users.
Click here to join!
3 notes · View notes
hepcure · 7 years ago
Text
Join our LIVE Webinar on Tuesday, September 5 on “HCV Among Women of Childbearing Age”
Please join us on Tuesday, September 5th at 4:30 PM EST for a presentation by Dr. Norah Terrault of the University of California San Francisco. Dr. Terrault will present: "HCV Among Women of Childbearing Age" Lecture Objectives: 1. Explain the epidemiology of the hepatitis C virus (HCV) 2. Discuss HCV screening among women of childbearing age 3. Describe HCV care during pregnancy Presenter Bio: Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation. She has authored more than 250 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology and is current Associate Editor for Hepatology Communications. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.
* Free Pre-Registration Required
Click here to join!
0 notes
hepcure · 7 years ago
Text
Watch Archived Webinar “Introducing the new New York State HCV Guidelines”
On Tuesday, August 29th, Dr. David Bernstein of the Hofstra-Northwell School of Medicine presented on: “Introduction to the new NYS HCV Guidelines” Lecture Objectives: 1. Explain the NYS recommendations for HCV treatment candidates 2. Summarize the current available therapies for HCV 3. Describe support systems recommended in NYS for patients with HCV Presenter Bio: David E. Bernstein, MD is Vice Chair of Clinical Trials, Chief, Division of Hepatology, and Director of the Sandra Atlas Bass Center for Liver Disease for the Northwell Health System. He is a Professor of Medicine and Educational Science at the Hofstra Northwell School of Medicine. Dr. Bernstein’s main research interest has been in field of liver diseases, with most of his work concentrated on developing new treatments for chronic hepatitis C. Dr. Bernstein’s main research interest has been in field of liver diseases, with most of his work concentrated on developing new treatments for chronic hepatitis C.
 Access the Webinar Here
Access the Slides Here
1 note · View note
hepcure · 7 years ago
Text
Join our LIVE Webinar on Tuesday, August 29 on “Introduction to the new New York State HCV Guidelines”
Please join us on Tuesday, August 29th at 4:30 PM EST for a presentation by Dr. David Bernstein of the Hofstra-Northwell School of Medicine. Dr. Bernstein will present: "Introduction to the new NYS HCV Guidelines" Lecture Objectives: 1. Explain the NYS recommendations for HCV treatment candidates 2. Summarize the current available therapies for HCV 3. Describe support systems recommended in NYS for patients with HCV Presenter Bio: David E. Bernstein, MD is Vice Chair of Clinical Trials, Chief, Division of Hepatology, and Director of the Sandra Atlas Bass Center for Liver Disease for the Northwell Health System. He is a Professor of Medicine and Educational Science at the Hofstra Northwell School of Medicine. Dr. Bernstein’s main research interest has been in field of liver diseases, with most of his work concentrated on developing new treatments for chronic hepatitis C. Dr. Bernstein’s main research interest has been in field of liver diseases, with most of his work concentrated on developing new treatments for chronic hepatitis C.
* Free Pre-Registration Required
Click here to join!
0 notes
hepcure · 7 years ago
Text
Watch Archived Webinar “Drug-Drug Interactions: What You Need to Know”
On Tuesday, August 22nd, Susan Lee, PharmD, of Northwell Health - Sandra Atlas Bass Center for Liver Diseases presented on: “Hepatitis C Drug-Drug Interactions: What You Need to Know” Lecture Objectives: 1. Describe basic pharmacokinetic principles as they relate to drug interactions 2. Describe the manifestation of drug interaction 3. Relate the drug interactions to the commercially available Hepatitis C medications 4. Provide resources regarding identifying drug interactions Presenter Bio: Dr. Susan MK Lee is a specialist pharmacist at the Sandra Atlas Bass Center for Liver Diseases part of Northwell Health. She is a certified diabetes educator and also has a board certification in pharmacy specialties. Dr. Lee currently works with an interdisciplinary team focused on providing access to high cost hepatitis C medications as well as pertinent patients education regarding potential drug interactions, proper medication administration, and appropriate follow up. She has helped over a thousand patients initiate hepatitis C medication regimen.
Access the Webinar Here
Access the Slides Here
0 notes
hepcure · 7 years ago
Text
Join our LIVE Webinar on Tuesday, August 22 on “HCV Drug-Drug Interactions: What You Need to Know”
Please join us on Tuesday, August 22nd at 4:30 PM EST for a presentation by Susan Lee, PharmD, of Northwell Health - Sandra Atlas Bass Center for Liver Diseases. Dr. Lee will present: "Hepatitis C Drug-Drug Interactions: What You Need to Know" Lecture Objectives: 1. Describe basic pharmacokinetic principles as they relate to drug interactions 2. Describe the manifestation of drug interaction 3. Relate the drug interactions to the commercially available Hepatitis C medications 4. Provide resources regarding identifying drug interactions Presenter Bio: Dr. Susan MK Lee is a specialist pharmacist at the Sandra Atlas Bass Center for Liver Diseases part of Northwell Health. She is a certified diabetes educator and also has a board certification in pharmacy specialties. Dr. Lee currently works with an interdisciplinary team focused on providing access to high cost hepatitis C medications as well as pertinent patients education regarding potential drug interactions, proper medication administration, and appropriate follow up. She has helped over a thousand patients initiate hepatitis C medication regimen.
* Free Pre-Registration Required
Click here to join!
0 notes
hepcure · 7 years ago
Text
Watch Archived Webinar “Treat Now or Wait? Acute HCV Infection”
On Tuesday, August 8th, Dr. Kenneth Sherman of the University of Cincinnati School of Medicine presented on: “Treat Now or Wait? Acute HCV Infection” Lecture Objectives: 1. Describe transmission and pathogenesis of hepatitis C virus (HCV) during initial infection 2. Identify the signs and symptoms associated with acute HCV infection 3. Discuss diagnostic algorithms and treatment options Presenter Bio: Kenneth E. Sherman received his BS & PhD (Microbiology) from Rutgers University and his MD from George Washington University. He is board certified in both Internal Medicine and Gastroenterology with a focus in Hepatology. Currently, he holds an endowed chair as the Gould Professor of Medicine, and serves as the Director of the Division of Digestive Diseases at the University of Cincinnati College of Medicine. Dr. Sherman’s research interests center around diagnosis and treatment of viral hepatitis and the pathogenesis, evaluation and treatment of liver disease in those with HIV infection.  Dr. Sherman is the author of over 250 articles, abstracts and book chapters on viral hepatitis and other areas of liver disease. He has edited two textbooks, most recently HIV and Liver Disease published in 2012. Dr. Sherman has held numerous leadership positions in the field, and is currently the Vice Chair of the Liver-Biliary Section of the American Gastroenterological Association (AGA). He has served on numerous Editorial Boards, and has chaired NIH Study sections as well as the FDA Antiviral Advisory Committee. Dr. Sherman is a Fellow of the American College of Physicians, the American Gastroenterologic Association, the American College of Gastroenterology and the American Association for the Study of Liver Disease.
Duration: 1 hour, 1 minute
Access the Webinar Here
Access the Slides Here
0 notes
hepcure · 7 years ago
Text
Join our LIVE Webinar on Tuesday, August 8 on “Treat Now or Wait? Acute HCV Infection”
Please join us on Tuesday, August 8th at 4:30 PM EST for a presentation by Dr. Kenneth Sherman. Dr. Sherman will present: "Treat Now or Wait? Acute HCV Infection" Lecture Objectives: 1. Describe transmission and pathogenesis of hepatitis C virus (HCV) during initial infection 2. Identify the signs and symptoms associated with acute HCV infection 3. Discuss diagnostic algorithms and treatment options Presenter Bio: Kenneth E. Sherman received his BS & PhD (Microbiology) from Rutgers University and his MD from George Washington University. He is board certified in both Internal Medicine and Gastroenterology with a focus in Hepatology. Currently, he holds an endowed chair as the Gould Professor of Medicine, and serves as the Director of the Division of Digestive Diseases at the University of Cincinnati College of Medicine. Dr. Sherman’s research interests center around diagnosis and treatment of viral hepatitis and the pathogenesis, evaluation and treatment of liver disease in those with HIV infection.  Dr. Sherman is the author of over 250 articles, abstracts and book chapters on viral hepatitis and other areas of liver disease. He has edited two textbooks, most recently HIV and Liver Disease published in 2012. Dr. Sherman has held numerous leadership positions in the field, and is currently the Vice Chair of the Liver-Biliary Section of the American Gastroenterological Association (AGA). He has served on numerous Editorial Boards, and has chaired NIH Study sections as well as the FDA Antiviral Advisory Committee. Dr. Sherman is a Fellow of the American College of Physicians, the American Gastroenterologic Association, the American College of Gastroenterology and the American Association for the Study of Liver Disease. Click here to join!
0 notes
hepcure · 8 years ago
Text
Watch Archived Webinar “HCV & Renal Disease”
On Tuesday, July 25th, Dr. Brett Fortune of NewYork-Presbyterian Hospital/Weill Cornell Medicine presented on: "HCV & Renal Disease" Lecture Objectives: 1. Discuss the association between Hepatitis C (HCV) and kidney disease and HCV's clinical impact 2. Discuss the currently available HCV treatment regimens for patients with advanced kidney disease as well as drugs in the pipeline 3. Discuss the current treatment strategies for renal transplant candidates or recipients with HCV Presenter Bio: Dr. Brett Fortune is a Transplant Hepatologist who joined the New York Presbyterian /Weill Cornell team in August 2016. Dr. Fortune received his medical degree from Wake Forest University School of Medicine in North Carolina, and then completed his Internal Medicine residency training at The Ohio State University Medical Center. He would then go on to obtain his Gastroenterology and Transplant Hepatology fellowship training at The University of Colorado in Denver, CO. Dr. Fortune’s clinical and research interests include clinical outcomes related to the complications of cirrhosis and portal hypertension as well as quality improvement in the care of patients with cirrhosis or those who have received a liver transplant. He has written several papers and book chapters in the field, actively participates as a reviewer for several journals, and is an active participant in many national academic societies.
Duration: 54 minutes
Access the Webinar Here
Access the Slides Here
0 notes
hepcure · 8 years ago
Text
Join our LIVE Webinar on Tuesday, July 25 on “HCV & Renal Disease”
Please join us on Tuesday, July 25th at 4:30 PM EST for a presentation by Dr. Brett Fortune of NewYork-Presbyterian Hospital/Weill Cornell Medicine. Dr. Fortune will present: "HCV & Renal Disease" Lecture Objectives: 1. Discuss the association between Hepatitis C (HCV) and kidney disease and HCV's clinical impact 2. Discuss the currently available HCV treatment regimens for patients with advanced kidney disease as well as drugs in the pipeline 3. Discuss the current treatment strategies for renal transplant candidates or recipients with HCV Presenter Bio: Dr. Brett Fortune is a Transplant Hepatologist who joined the New York Presbyterian /Weill Cornell team in August 2016. Dr. Fortune received his medical degree from Wake Forest University School of Medicine in North Carolina, and then completed his Internal Medicine residency training at The Ohio State University Medical Center. He would then go on to obtain his Gastroenterology and Transplant Hepatology fellowship training at The University of Colorado in Denver, CO. Dr. Fortune’s clinical and research interests include clinical outcomes related to the complications of cirrhosis and portal hypertension as well as quality improvement in the care of patients with cirrhosis or those who have received a liver transplant. He has written several papers and book chapters in the field, actively participates as a reviewer for several journals, and is an active participant in many national academic societies.
Click here to join!
0 notes
hepcure · 8 years ago
Text
Watch Archived Webinar “Treatment for HCV: New Tests, New Drugs & New Recommendations”
On Tuesday, July 11th, Dr. Kristen Marks of the Cornell University Weill Cornell Medical College presented on: “Treatment for HCV: New Tests, New Drugs, New Recommendations” Lecture Objectives: 1. Explain the epidemiology of the hepatitis C virus (HCV) 2. Discuss laboratory testing and diagnosis of HCV infection 3. Design a therapeutic regimen and monitoring plan for the treatment of HCV Presenter Bio: Dr. Marks received her medical degree from Columbia University College of Physicians and Surgeons and completed her Internal Medicine residency and Infectious Diseases fellowship training at New York-Presbyterian Hospital (NYPH) - Cornell. She focused her clinical training and research on HIV and hepatitis virus infections while completing Weill Cornell’s Master’s Degree in Clinical Investigation. She now cares for patients in New York-Presbyterian Hospital’s Hepatitis and HIV clinics and serves as an investigator in the Cornell Clinical Trials Unit and Center for Study of Hepatitis C. Her current research focuses on improving treatment outcomes in patients with HIV and hepatitis virus co-infections and includes studies of acute HCV as well as new treatment strategies for chronic HCV.
Duration: 1 hour, 4 minutes
Access the Webinar Here
Access the Slides Here
0 notes
hepcure · 8 years ago
Text
Join our LIVE Webinar on Tuesday, July 11 on “Treatment for HCV: New Tests, New Drugs, New Recommendations”
Please join us on Tuesday, July 11th at 4:30 PM EST for a presentation by Dr. Kristen Marks of the Cornell University Weill Cornell Medical College. Dr. Marks will present: "Treatment for HCV: New Tests, New Drugs, New Recommendations" Lecture Objectives: 1. Explain the epidemiology of the hepatitis C virus (HCV) 2. Discuss laboratory testing and diagnosis of HCV infection 3. Design a therapeutic regimen and monitoring plan for the treatment of HCV Presenter Bio: Dr. Marks received her medical degree from Columbia University College of Physicians and Surgeons and completed her Internal Medicine residency and Infectious Diseases fellowship training at New York-Presbyterian Hospital (NYPH) - Cornell. She focused her clinical training and research on HIV and hepatitis virus infections while completing Weill Cornell's Master's Degree in Clinical Investigation. She now cares for patients in New York-Presbyterian Hospital’s Hepatitis and HIV clinics and serves as an investigator in the Cornell Clinical Trials Unit and Center for Study of Hepatitis C. Her current research focuses on improving treatment outcomes in patients with HIV and hepatitis virus co-infections and includes studies of acute HCV as well as new treatment strategies for chronic HCV.
Click here to join!
0 notes
hepcure · 8 years ago
Text
Watch Archived Webinar
On Tuesday, June 27th, Dr. Douglas Dieterich of the Icahn School of Medicine at Mount Sinai presented on: "Fever and elevated liver enzymes in a woman returning from India & other cases from the field" Lecture Objectives: 1. To explore the differential diagnosis of elevated alt 2. To describe the etiology of fever and elevated alt 3. To list the cases of diseases in patients returning from India Presenter Bio: Douglas Dieterich, MD, is currently Professor of Medicine in the Division of Liver Diseases and also Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine, New York, NY. He has a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases. He graduated from Yale University and received his Doctorate of Medicine from New York University School of Medicine. He completed his internship and residency in Internal Medicine at the Bellevue Hospital Centre in New York, NY, where he was also a Fellow in the Division of Gastroenterology. He became Clinical Assistant Professor of Medicine and then Clinical Professor of Medicine, both at New York University and remains as an Adjunct Clinical Professor of Medicine at New York University School of Medicine. Dr. Dieterich is an investigator for many ongoing clinical trials of new antiviral treatments for chronic hepatitis B & C. He is a member of many professional societies and has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health (NIH). Widely published, Dr. Dieterich is the author of numerous journal articles, abstracts and book chapters on viral hepatitis and AIDS-associated infections of the gastrointestinal tract and liver.
Duration: 58 minutes
Access the Webinar Here
Access the Slides Here & Here
0 notes
hepcure · 8 years ago
Text
Join our LIVE Webinar on Tuesday, June 27 on Case Presentation
Please join us on Tuesday, June 27th at 4:30 PM EST for a presentation by Dr. Douglas Dieterich of the Icahn School of Medicine at Mount Sinai. Dr. Dieterich will present: "Fever and elevated liver enzymes in a woman returning from India & other cases" Lecture Objectives: 1. To explore the differential diagnosis of elevated alt 2. To describe the etiology of fever and elevated alt 3. To list the cases of diseases in patients returning from India Presenter Bio: Douglas Dieterich, MD, is currently Professor of Medicine in the Division of Liver Diseases and also Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine, New York, NY. He has a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases. He graduated from Yale University and received his Doctorate of Medicine from New York University School of Medicine. He completed his internship and residency in Internal Medicine at the Bellevue Hospital Centre in New York, NY, where he was also a Fellow in the Division of Gastroenterology. He became Clinical Assistant Professor of Medicine and then Clinical Professor of Medicine, both at New York University and remains as an Adjunct Clinical Professor of Medicine at New York University School of Medicine. Dr. Dieterich is an investigator for many ongoing clinical trials of new antiviral treatments for chronic hepatitis B & C. He is a member of many professional societies and has served on several committees of the AIDS Clinical Trials Group at the National Institutes of Health (NIH). Widely published, Dr. Dieterich is the author of numerous journal articles, abstracts and book chapters on viral hepatitis and AIDS-associated infections of the gastrointestinal tract and liver. Click here to join!
0 notes
hepcure · 8 years ago
Text
Watch Archived Webinar “The Road to HCV Elimination in San Francisco”
On Tuesday, June 20th, Katie Burk of the San Francisco Department of Public Health and Emalie Huriaux of Project Inform and the California Hepatitis Alliance presented on: “The Road to HCV Elimination: Policy and Collective Impact in San Francisco”
About Katie Burk: Katie is the Viral Hepatitis Coordinator at the San Francisco Department of Public Health where she oversees hepatitis programming and works on related drug user health issues. She is a co-founder and Coordinating Committee member of End Hep C SF and serves on the Governance Council of SF Hep B Free. Prior to her employment at SFDPH, Ms. Burk worked as a Capacity-Building Program Manager at the Harm Reduction Coalition, where she worked nationally to expand syringe access service provision, and as a Program Evaluator at Public Health Seattle & King County’s Health Care for the Homeless team. Ms. Burk started her career as a case manager for San Franciscans living with HIV. She received her Master of Public Health degree at the University of Washington School of Public Health in the Community-Oriented Public Health Practice program. About Emalie Huriaux: Emalie Huriaux is the Director of Federal & State Affairs for Project Inform, a 32 year old nonprofit organization working to end the HIV and hepatitis C epidemics through advocacy and education. In this role she is responsible for the organization’s national and California-based hepatitis C policy activities. In addition, she chairs the California Hepatitis Alliance, a statewide coalition of nearly 100 member organizations working together to end hepatitis B and C in the state. She also serves as the Steering Committee chair for the National Viral Hepatitis Roundtable (a broad coalition working to fight, and ultimately end, the hepatitis B and hepatitis C epidemics), and is co-chair of the Fair Pricing Coalition (an ad hoc group of activists who advocate with the pharmaceutical industry regarding the price of HIV and hepatitis drugs). Prior to these roles, she worked for seven years at the San Francisco Department of Public Health, where Ms. Huriaux served as the Viral Hepatitis & Integration Coordinator, and spent many years as a health educator and front line provider working with harm reduction programs, including street outreach, syringe access, overdose prevention, and sexual health programs.
Duration: 1 hour
Access the Webinar Here
Access the Slides Here
0 notes